TransMedics Group, Inc. (TMDX) Revenue
The trailing-twelve-month (TTM) revenue for TransMedics Group, Inc. (TMDX) is $635.89 Million with a year-over-year growth of +30.24%. Revenue represents the total income generated from the company's primary business operations.
TMDX Annual Revenue
Revenue (TTM)
$635.89M
$635.89 Million
Year-over-Year Growth
+30.24%
vs. $488.24M a year ago (TTM)
Revenue CAGR
+90.79%
5 Year compound annual growth rate
Revenue CAGR (Compound Annual Growth Rate)
1 Year
+30.24%
3 Year
+74.74%
5 Year
+90.79%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Revenue History
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $605.49M | +$163.95M | +37.13% |
| 2024 | $441.54M | +$199.92M | +82.74% |
| 2023 | $241.62M | +$148.16M | +158.53% |
| 2022 | $93.46M | +$63.20M | +208.83% |
| 2021 | $30.26M | +$4.62M | +18.03% |
| 2020 | $25.64M | +$2.04M | +8.62% |
| 2019 | $23.60M | +$10.59M | +81.33% |
| 2018 | $13.02M | +$5.33M | +69.38% |
| 2017 | $7.68M | +$1.48M | +23.77% |
Revenue Growth Summary
TTM Growth
+30.24%
3-Year Avg Growth
+74.74%
5-Year Avg Growth
+90.79%
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein